Form 4: Ionis Pharmaceuticals Director Michael Hayden Receives Routine Equity Grants

Ionis Pharmaceuticals Director Michael R. Hayden was granted 11,518 non-qualified stock options and 5,220 restricted stock units on July 1, 2025, as part of the company's non-employee director compensation policy.

Summary

• Michael R. Hayden, a Director at Ionis Pharmaceuticals Inc. (IONS), received equity grants on July 1, 2025.
• The grants include 11,518 non-qualified stock options with an exercise price of $39.94.
• Also granted were 5,220 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These grants are part of the Company's Non-Employee Director Compensation Policy, ensuring the Director's annual equity compensation for 2025 does not exceed $450,000 based on aggregate grant date fair value (FASB Topic ASC 718).
• Both the stock options and RSUs vest 100% on the first anniversary of the grant date (July 1, 2026) or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier.
• The RSUs will be delivered to the reporting person on July 15th following the vesting date.

Sentiment

Score: 7

Explanation: The document is a routine Form 4 filing detailing standard director compensation. It reflects normal corporate governance and compensation practices, which is a neutral to slightly positive indicator of stability and adherence to policy. No negative or significantly positive operational news is conveyed.

Positives

• Grants align with a structured Non-Employee Director Compensation Policy, indicating a clear framework for executive incentives.
• The equity grants incentivize long-term alignment between director interests and shareholder value through vesting schedules.
• The total annual equity compensation for non-employee directors is capped at $450,000, demonstrating a controlled approach to compensation.

Future Outlook

The grants indicate a continued commitment to aligning director incentives with long-term company performance through equity-based compensation, with vesting scheduled for July 1, 2026, or earlier based on the next annual stockholders' meeting.

Management Comments

• Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
• Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Industry Context

This Form 4 filing is a routine disclosure of director equity compensation, common in the biotechnology and pharmaceutical industries to attract and retain experienced board members. Such compensation structures are standard practice to align the interests of directors with long-term shareholder value, particularly in R&D-intensive sectors like biotech where long-term strategic oversight is crucial.

Comparison to Industry Standards

• The use of stock options and restricted stock units for non-employee director compensation is a standard practice across the biotechnology and pharmaceutical industries, comparable to compensation structures at companies like Amgen, Gilead Sciences, or Biogen.
• The vesting schedule, tied to either the first anniversary of the grant or the next annual meeting, is typical for director equity awards, ensuring continued service and alignment.
• The cap on annual equity compensation ($450,000) is within a reasonable range for non-employee directors at a company of Ionis's size and market capitalization, similar to policies observed at mid-to-large cap biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants align director interests with shareholder value through equity ownership and performance incentives. The compensation policy ensures a cap on equity awards, potentially benefiting shareholders by controlling compensation costs.

Next Steps

• The granted stock options and Restricted Stock Units will vest on July 1, 2026, or the next regularly scheduled annual meeting of stockholders, whichever is earlier.
• Restricted Stock Units will be delivered to the reporting person on July 15th following their vesting date.

Key Dates

Recommendation

Keywords

Ionis Pharmaceuticals, IONS, SEC Form 4, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Michael R. Hayden, Corporate Governance, Biotechnology, Pharmaceuticals